Literature DB >> 3283320

Metabolism of angiotensins II and III by membrane-bound peptidases from rat brain.

R H Abhold1, J W Harding.   

Abstract

This study examines the metabolism of 125I-angiotensin II (125I-ANG II) and 125I-angiotensin III (applied 125I-ANG III or 125I-ANG IIIapp) by membrane peptidases. The first step in the metabolism of 125I-ANG II was the formation of 125I-ANG III (generated 125I-ANG III or 125I-ANG IIIgen). The ability of both ANG II and ANG III to reduce 125I-ANG IIIgen production without ANG(1-5), ANG(2-5), amastatin or bestatin being similarly effective suggests that this step may be highly substrate-specific. Subsequent metabolism of 125I-ANG IIIgen was similar to that of 125I-ANG IIIapp in that 125I-ANG(2-7) and 125I-ANG(2-4) fragments were produced. The formation of 125I-ANG(2-7) appeared to be a very substrate-specific process because it was only inhibited by ANG II and ANG III. In contrast, the production of 125I-ANG(2-4) was unaffected at the concentration of inhibitors used and is considered to be a relatively nonspecific process. However, despite these similarities sequential N-terminal cleavage leading to the formation of 125I-ANG(3-8), 125I-ANG(4-8) and 125I-Tyrosine appears to be the preferred pathway in the metabolism of 125I-ANG IIIapp. The absence of this pathway in the metabolism of 125I-ANG IIIgen suggests that applied and generated 125I-ANG III may be metabolized in separate degradative compartments. These data demonstrate that 125I-ANG II and 125I-ANG III are metabolized by membrane-bound peptidases in an orderly and sequential manner.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs.

Authors:  Caroline C Benoist; John W Wright; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2011-06-30       Impact factor: 4.030

3.  Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria.

Authors:  Q Li; J Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Angiotensin receptors from rat liver, brain and pituitary gland. Expression of two subtypes in Xenopus oocytes.

Authors:  B Cantau; S Bartolami; P P Baskevitch; F Desarnaud; D Chicot; S Jard
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

5.  Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta.

Authors:  Q Li; L Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

6.  Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.

Authors:  Alene T McCoy; Caroline C Benoist; John W Wright; Leen H Kawas; Jyote M Bule-Ghogare; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

Review 7.  Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges.

Authors:  Vardan T Karamyan; Robert C Speth
Journal:  Regul Pept       Date:  2007-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.